Biosimilar Update
Join us on June 8, 2021 | 5 - 6pm MT
Join us for a rapid-fire presentation from 6 pharmaceutical companies on the biosimilar options available for prescription when Adalimumab is desired. We will review the change in prescribing patterns required by the Alberta government for the use of Humira and learn about the patient support programs available for biosimilars.
Program:
- 5:00 – 5:05 PM: Opening Remarks by Tarun Misra – ASG Incoming President
- 5:05 – 5:10 PM: Remarks by AbbVie
- 5:10 – 5:35 PM: 5 mins each, order drawn from hat
- Pendopharm/Sandoz (Hyrimoz)
- Fresenius/Kabi (Idacio)
- Mylan/FujiFilm (Hulio)
- Merck/Samsung (Hadlima)
- Amgen (Amgevita)
- 5:35 – 5:45 PM: Q&A
- 5:45 - 6:15 PM: ASG Private Meeting
Learning Objectives:
- Understand the change in prescribing patterns required by the Alberta government for the use of Humira
- Identify the possible biosimilar options available for prescription when Adalimumab is desired
- Learn the patient support programs available for biosimilars
Registration
The registration link has been provided to all ASG Members.
If you have any questions, please reach out to ASG@buksa.com.